2 Information about tezepelumab

Marketing authorisation indication

2.1 Tezepelumab (Tezspire, AstraZeneca) is indicated as 'an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for tezepelumab.


2.3 The list price for tezepelumab is £1,265 per 210 mg prefilled syringe per vial (company submission, May 2022). The company has a commercial arrangement. This makes tezepelumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.